Blue California Commercializes Nicotinamide Mononucleotide (NMN) for Supporting an Increased Healthspan
Rancho Santa Margarita, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Blue California joins with the innovative Massachusetts-based biotech company Conagen to announce the commercialization of high-purity, fermentation-derived nicotinamide mononucleotide (NMN).
- Rancho Santa Margarita, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Blue California joins with the innovative Massachusetts-based biotech company Conagen to announce the commercialization of high-purity, fermentation-derived nicotinamide mononucleotide (NMN).
- Consumers are reassessing their dietary regimen to make room for ingredients that can support an increased healthspan, said Chief Science Officer at Blue California, Dr. Priscilla Samuel.
- Blue Californias fermentation-derived NMN opens new opportunities for producers to consider consumers' health more holistically while acquiring a closer-to-nature position.
- It is also very cost-effective and compatible with clean-label trends, all of which demonstrates our strength as a strategic partner with Blue California.